How Biologics Work

Biologic therapies are medications derived from living cells. They target specific proteins and immune cells that drive airway inflammation rather than suppressing the immune system broadly. That precision is what sets them apart from corticosteroids and other conventional treatments.

Each biologic is designed to interrupt a distinct part of the inflammatory process. Some block proteins that promote the growth of eosinophils, a type of white blood cell central to airway inflammation. Others target immunoglobulin E, an antibody involved in allergic reactions. Newer biologics go further upstream, blocking proteins called alarmins that activate multiple inflammatory pathways at once. A 2025 review in Current Pediatrics Reports outlines how these targeted approaches have fundamentally shifted the management of severe asthma.

Most biologics are administered by injection on a schedule ranging from every two weeks to every six months, depending on the specific medication.

Why Asthma Type Matters Before Prescribing

Biologics aren't prescribed based on asthma severity alone. Providers first need to identify which immune pathway is driving the inflammation in a given patient, because different biologics work on different targets.

Eosinophilic asthma is one of the most common subtypes treated with biologics. It involves elevated eosinophil activity in the airways and is identified through blood tests measuring eosinophil counts. Allergic asthma involves a strong immune response to environmental triggers and is assessed through IgE levels and allergen sensitivity testing. A comprehensive review in the Journal of Allergy and Clinical Immunology describes how these biomarkers are used together to classify patients and guide treatment decisions.

Fractional exhaled nitric oxide, known as FeNO, is another diagnostic tool that measures airway inflammation directly. Elevated FeNO levels point toward a type of inflammation that's likely to respond well to certain biologics. According to research published in CHEST, combining blood eosinophil counts with FeNO measurements gives providers a clearer picture of which patients will benefit most from biologic treatment.

Who Qualifies for Biologic Treatment

Biologics are add-on treatments, not starting points. They're considered when a patient has persistent, uncontrolled asthma despite consistent use of high-dose inhaled corticosteroids and other controller medications.

Providers assess several factors before recommending a biologic. Frequency of severe flare-ups carries weight, as does a history of repeated oral corticosteroid use. Long-term oral steroid therapy carries serious risks including bone density loss, elevated blood sugar, and immune suppression. Reducing that steroid burden is one of the primary clinical reasons biologics are now more widely used, as noted in guidelines from the European Respiratory Society.

A 2024 real-world analysis published in the Journal of Clinical Medicine found that biologic therapies produced meaningful reductions in exacerbation rates, emergency visits, and hospitalizations among patients who hadn't responded to conventional treatment.

What the Evidence Shows

Clinical trial data for approved biologics in severe asthma is strong. Patients with the relevant biomarker profiles consistently show fewer exacerbations, better lung function, and reduced reliance on oral steroids after starting biologic treatment.

Research is also moving toward less frequent dosing. A phase 3 trial published in the New England Journal of Medicine found that a newer biologic administered twice yearly significantly reduced exacerbations in patients with severe eosinophilic asthma, a development that could meaningfully improve treatment adherence over time.

Switching from one biologic to another is also becoming more common when initial results are insufficient. A 2025 PMC review on biologic therapy for severe asthma outlines how providers evaluate treatment response and make those decisions based on ongoing biomarker monitoring.

Questions Worth Raising With a Doctor

Patients who think they might be candidates for biologic therapy have a few specific questions worth bringing to their next appointment.

The first is whether their asthma subtype has been formally identified through biomarker testing. Without that step, it's not possible to match a patient to the right biologic. A biomarker review from Allergy, Asthma and Clinical Immunology recommends that all patients being considered for biologics undergo eosinophil count testing, IgE measurement, and allergen sensitivity assessment as a baseline.

Other useful questions include how long it typically takes to see results, what side effects have been reported, and whether the medication can be self-administered at home. Cost and insurance coverage are practical matters worth discussing early, since biologic therapies can be expensive and prior authorization requirements vary widely.

Biologic therapies have changed the outlook for people with severe asthma who weren't getting adequate control from standard treatment. They're well studied, precisely targeted and, for the right patient, they can substantially reduce the burden of living with difficult, unpredictable asthma.